Skip to main content
Article
Fibrinogen, Chronic Obstructive Pulmonary Disease (COPD) and Outcomes in Two United States Cohorts
International Journal of Chronic Obstructive Pulmonary Disease
  • Deepa Valvi, University of Kentucky
  • David M. Mannino, University of Kentucky
  • Hana Müllerova, GlaxoSmithKline, United Kingdom
  • Ruth Tal-Singer, GlaxoSmithKline
Abstract
BACKGROUND: Fibrinogen is a marker of systemic inflammation and may be important in the pathogenesis and progression of chronic obstructive pulmonary disease (COPD). METHODS: We used baseline data from Atherosclerosis Risk in Communities and Cardiovascular Health Studies to determine the relation between fibrinogen levels and COPD and to examine how fibrinogen levels at baseline affected outcomes of death, development of COPD, lung function decline, and COPD-hospitalizations. RESULTS: Our study sample included 20,192 subjects, of whom 2995 died during the follow-up period. The mean fibrinogen level was 307.6 mg/dL and 10% of the sample had levels >393.0 mg/dL. Subjects with Stage 3 or 4 COPD were more likely to have a fibrinogen level >393.0 mg/dL (odds ratio 2.28, 95% confidence interval [CI]: 1.79-2.95). In the longitudinal adjusted models, fibrinogen levels >393 mg/dL predicted mortality (hazards ratio 1.54, 95% CI: 1.39-1.70), COPD-related hospitalization (hazards ratio 1.45, 95% CI: 1.27-1.67), and incident Stage 2 COPD (odds ratio 1.36, 95% CI: 1.07-1.74). Similar findings were seen with continuous fibrinogen levels. CONCLUSION: In the Atherosclerosis Risk in Communities/Cardiovascular Health Studies cohort data, higher fibrinogen levels are predictors of mortality, COPD-related hospitalizations, and incident Stage 2 COPD.
Document Type
Article
Publication Date
3-6-2012
Notes/Citation Information

Published in International Journal of Chronic Obstructive Pulmonary Disease, v. 7, p. 173-182.

This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Digital Object Identifier (DOI)
http://dx.doi.org/10.2147/COPD.S29892
Citation Information
Deepa Valvi, David M. Mannino, Hana Müllerova and Ruth Tal-Singer. "Fibrinogen, Chronic Obstructive Pulmonary Disease (COPD) and Outcomes in Two United States Cohorts" International Journal of Chronic Obstructive Pulmonary Disease Vol. 7 (2012) p. 173 - 182
Available at: http://works.bepress.com/david_mannino/267/